Invesco’s Veracyte VCYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $14.1M | Buy |
436,587
+45,817
| +12% | +$1.7M | ﹤0.01% | 1647 |
|
|
2025
Q4 | $16.5M | Sell |
390,770
-88,830
| -19% | -$3.58M | ﹤0.01% | 1572 |
|
|
2025
Q3 | $16.5M | Buy |
479,600
+159,037
| +50% | +$4.56M | ﹤0.01% | 1551 |
|
|
2025
Q2 | $8.66M | Buy |
320,563
+21,373
| +7% | +$619K | ﹤0.01% | 1869 |
|
|
2025
Q1 | $8.87M | Sell |
299,190
-30,378
| -9% | -$1.16M | ﹤0.01% | 1848 |
|
|
2024
Q4 | $13.1M | Buy |
329,568
+7,042
| +2% | +$267K | ﹤0.01% | 1695 |
|
|
2024
Q3 | $11M | Sell |
322,526
-89,251
| -22% | -$2.51M | ﹤0.01% | 1792 |
|
|
2024
Q2 | $8.92M | Buy |
411,777
+53,403
| +15% | +$1.12M | ﹤0.01% | 1858 |
|
|
2024
Q1 | $7.94M | Buy |
358,374
+29,030
| +9% | +$708K | ﹤0.01% | 1951 |
|
|
2023
Q4 | $9.06M | Sell |
329,344
-147,005
| -31% | -$3.55M | ﹤0.01% | 1878 |
|
|
2023
Q3 | $10.6M | Buy |
476,349
+132,310
| +38% | +$3.4M | ﹤0.01% | 1718 |
|
|
2023
Q2 | $8.76M | Sell |
344,039
-45,056
| -12% | -$1.09M | ﹤0.01% | 1893 |
|
|
2023
Q1 | $8.68M | Buy |
389,095
+75,121
| +24% | +$1.82M | ﹤0.01% | 1906 |
|
|
2022
Q4 | $7.45M | Sell |
313,974
-98,670
| -24% | -$2.29M | ﹤0.01% | 2042 |
|
|
2022
Q3 | $6.85M | Sell |
412,644
-3,525,022
| -90% | -$79.3M | ﹤0.01% | 2031 |
|
|
2022
Q2 | $78.4M | Sell |
3,937,666
-193,931
| -5% | -$3.92M | 0.02% | 773 |
|
|
2022
Q1 | $114M | Buy |
4,131,597
+17,566
| +0.4% | +$502K | 0.03% | 725 |
|
|
2021
Q4 | $169M | Buy |
4,114,031
+181,381
| +5% | +$8.01M | 0.04% | 575 |
|
|
2021
Q3 | $183M | Sell |
3,932,650
-313,920
| -7% | -$13.7M | 0.05% | 552 |
|
|
2021
Q2 | $170M | Buy |
4,246,570
+57,275
| +1% | +$2.45M | 0.04% | 610 |
|
|
2021
Q1 | $225M | Buy |
4,189,295
+621,710
| +17% | +$35.8M | 0.06% | 412 |
|
|
2020
Q4 | $175M | Sell |
3,567,585
-63,144
| -2% | -$2.93M | 0.05% | 494 |
|
|
2020
Q3 | $118M | Buy |
3,630,729
+421,552
| +13% | +$13.4M | 0.04% | 573 |
|
|
2020
Q2 | $83.1M | Sell |
3,209,177
-13,387
| -0.4% | -$334K | 0.03% | 670 |
|
|
2020
Q1 | $78.3M | Sell |
3,222,564
-115,325
| -3% | -$2.9M | 0.03% | 598 |
|
|
2019
Q4 | $93.2M | Buy |
3,337,889
+114,182
| +4% | +$2.96M | 0.03% | 699 |
|
|
2019
Q3 | $77.4M | Buy |
3,223,707
+237,962
| +8% | +$6.33M | 0.02% | 772 |
|
|
2019
Q2 | $85.1M | Buy |
2,985,745
+2,390,394
| +402% | +$59.7M | 0.02% | 755 |
|
|
2019
Q1 | $14.9M | Buy |
595,351
+481,594
| +423% | +$9.2M | 0.01% | 1390 |
|
|
2018
Q4 | $1.43M | Buy |
113,757
+73,711
| +184% | +$872K | ﹤0.01% | 2762 |
|
|
2018
Q3 | $382K | Buy |
40,046
+8,577
| +27% | +$94.6K | ﹤0.01% | 3536 |
|
|
2018
Q2 | $294K | Buy |
31,469
+18,332
| +140% | +$129K | ﹤0.01% | 3604 |
|
|
2018
Q1 | $73K | Buy |
13,137
+1,501
| +13% | +$9.29K | ﹤0.01% | 3674 |
|
|
2017
Q4 | $76K | Buy |
11,636
+300
| +3% | +$2.23K | ﹤0.01% | 3614 |
|
|
2017
Q3 | $99K | Buy |
11,336
+443
| +4% | +$3.6K | ﹤0.01% | 3611 |
|
|
2017
Q2 | $91K | Buy |
+10,893
| New | +$88.9K | ﹤0.01% | 3651 |
|
|
2015
Q3 | – | Sell |
-470
| Closed | -$5K | – | 3999 |
|
|
2015
Q2 | $5K | Buy |
+470
| New | +$4.63K | ﹤0.01% | 4217 |
|
Other funds holding VCYT
VPM
VCM
AIM
Invesco's VCYT Position: Q1 2026 in Review
Invesco increased its Veracyte (VCYT) stake by 12% in Q1 2026, buying an estimated $1.7M and bringing the position to 436,587 shares worth $14.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1647.
Invesco first reported a position in VCYT in Q2 2015 and has held it in 37 quarters since. The position peaked at $225M in Q1 2021. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.
- Invesco held 436,587 shares of Veracyte worth $14.1M as of Q1 2026.
- Invesco bought 45,817 Veracyte shares in Q1 2026, an estimated $1.7M.
- Veracyte made up ﹤0.01% of Invesco's portfolio in Q1 2026, its #1647 holding.
- Invesco first reported a position in Veracyte in Q2 2015 and has held it in 37 quarters since.
- Invesco's Veracyte position peaked at $225M in Q1 2021.
- 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.
Based on Invesco's 13F filing for Q1 2026, filed 12 May 2026.